J J McMurray

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. ncbi request reprint Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Am Heart J 151:985-91. 2006
  2. pmc Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study
    Karen J Macpherson
    NHS Quality Improvement Scotland, Glasgow, UK
    BMC Neurol 11:38. 2011
  3. ncbi request reprint Why we need new strategies in CHF management
    J McMurray
    University of Glasgow, Glasgow, G12 8QQ, UK
    J Renin Angiotensin Aldosterone Syst 1:12-6. 2000
  4. ncbi request reprint Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom
    Kidney Int 68:1419-26. 2005
  5. ncbi request reprint Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
    Eur J Heart Fail 7:710-21. 2005
  6. ncbi request reprint Heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, UK
    Lancet 365:1877-89. 2005
  7. ncbi request reprint Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice
    J McMurray
    Clinical Research Initiative in Heart Failure, Glasgow, Scotland G11 6NT, UK
    Eur J Heart Fail 3:495-502. 2001
  8. ncbi request reprint Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, G12 8QQ, UK
    Circulation 110:3281-8. 2004
  9. ncbi request reprint Angiotensin inhibition in heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, UK
    J Renin Angiotensin Aldosterone Syst 5:S17-22. 2004
  10. ncbi request reprint Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    John J V McMurray
    University of Glasgow, Scotland
    Nat Clin Pract Cardiovasc Med 2:128-9. 2005

Detail Information

Publications108 found, 100 shown here

  1. ncbi request reprint Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Am Heart J 151:985-91. 2006
    ..Whether an angiotensin receptor blocker is of benefit when added to a full dose of angiotensin-converting enzyme (ACE) inhibitor in heart failure (HF) is uncertain...
  2. pmc Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study
    Karen J Macpherson
    NHS Quality Improvement Scotland, Glasgow, UK
    BMC Neurol 11:38. 2011
    ..To examine age and sex specific incidence and 30 day case fatality for subarachnoid haemorrhage (SAH) in Scotland over a 20 year period...
  3. ncbi request reprint Why we need new strategies in CHF management
    J McMurray
    University of Glasgow, Glasgow, G12 8QQ, UK
    J Renin Angiotensin Aldosterone Syst 1:12-6. 2000
    ....
  4. ncbi request reprint Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom
    Kidney Int 68:1419-26. 2005
  5. ncbi request reprint Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
    Eur J Heart Fail 7:710-21. 2005
    ..These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines...
  6. ncbi request reprint Heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, UK
    Lancet 365:1877-89. 2005
    ..Many new pharmacological, device, and surgical treatments for heart failure are currently under evaluation in clinical trials, and other approaches, including stem-cell treatment, are at an earlier stage of investigation...
  7. ncbi request reprint Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice
    J McMurray
    Clinical Research Initiative in Heart Failure, Glasgow, Scotland G11 6NT, UK
    Eur J Heart Fail 3:495-502. 2001
    ..These practical recommendations are meant to supplement rather than replace existing guidelines...
  8. ncbi request reprint Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, G12 8QQ, UK
    Circulation 110:3281-8. 2004
  9. ncbi request reprint Angiotensin inhibition in heart failure
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, UK
    J Renin Angiotensin Aldosterone Syst 5:S17-22. 2004
    ..Candesartan had expected effects on blood pressure and renal function, emphasising the need for careful patient monitoring...
  10. ncbi request reprint Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    John J V McMurray
    University of Glasgow, Scotland
    Nat Clin Pract Cardiovasc Med 2:128-9. 2005
  11. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    John J V McMurray
    University of Glasgow, Glasgow, UK
    Lancet 362:767-71. 2003
    ..We aimed to find out whether these drugs improve clinical outcome...
  12. ncbi request reprint Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme
    J McMurray
    Department of Cardiology, Western Infirmary, University of Glasgow, Glasgow G11 6NT, Scotland, UK
    Eur J Heart Fail 5:261-70. 2003
    ....
  13. pmc Heart failure in 10 years time: focus on pharmacological treatment
    J J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow G11 6NT, UK
    Heart 88:ii40-6. 2002
  14. ncbi request reprint New therapeutic options in congestive heart failure: Part II
    John McMurray
    Clinical Research Initiative in Heart Failure, University of Glasgow, Scotland
    Circulation 105:2223-8. 2002
  15. ncbi request reprint The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom
    J Am Coll Cardiol 47:726-33. 2006
    ..We attempted to compare the effect of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events...
  16. ncbi request reprint Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials
    John J V McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, United Kingdom
    JAMA 298:2009-19. 2007
    ..Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemodynamic actions in heart failure...
  17. ncbi request reprint Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, United Kingdom
    J Am Coll Cardiol 45:525-30. 2005
    ..Whether beta-blockers reduce atrial arrhythmias and, when added to an angiotensin-converting enzyme (ACE) inhibitor, ventricular arrhythmia is unknown...
  18. doi request reprint Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis
    John J V McMurray
    British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
    Circulation 120:2188-96. 2009
    ..We examined whether the antiinflammatory action of statins may be of benefit in heart failure, a state characterized by inflammation in which low cholesterol is associated with worse outcomes...
  19. doi request reprint Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure
    John J V McMurray
    BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom
    Circ Heart Fail 1:17-24. 2008
    ..This may overcome ACE inhibition but should be blocked by a direct renin inhibitor. We studied the effects of adding the direct renin inhibitor aliskiren to an ACE inhibitor in patients with heart failure...
  20. doi request reprint Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
    John J V McMurray
    British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
    Eur J Heart Fail 11:795-801. 2009
    ..The primary endpoint is the time to death from any cause or first hospital admission for worsening HF, whichever occurs first. The study will complete when approximately 1150 subjects experience a primary endpoint...
  21. ncbi request reprint Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    John J V McMurray
    Department of Cardiology, Level 4, Western Infirmary, Glasgow, Scotland, UK
    Eur Heart J 27:1447-58. 2006
    ..We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme...
  22. ncbi request reprint Treatment of chronic heart failure: a comparison between the major guidelines
    John McMurray
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Eur Heart J 27:1773-7. 2006
    ..Possible explanations for discrepancies between the guidelines are discussed. Future approaches that might clarify the grade of evidence allocated and class of recommendation made are also described...
  23. ncbi request reprint Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
    M P Love
    Medical Research Council Clinical Research Initiative in Heart Failure, University of Glasgow, Scotland, UK
    Circulation 94:2131-7. 1996
    ..We also compared the function of ETA and ETB receptors in healthy subjects and patients with CHF...
  24. ncbi request reprint Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
    M C Petrie
    Clinical Research Initiative in Heart Failure, University of Glasgow, Scotland, United Kingdom
    J Am Coll Cardiol 37:1056-61. 2001
    ..These studies suggest that full suppression of the renin-angiotensin system cannot be achieved by ACE inhibition alone and provide a rationale for developing future therapeutic strategies...
  25. ncbi request reprint Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986--1996
    S Stewart
    CRI in Heart Failure, Department of Public Health, The University of Glasgow, Glasgow, Scotland, UK
    Eur Heart J 22:693-701. 2001
    ..g. coding or admission thresholds) or both. Consequently, the public health burden of atrial fibrillation is enormous. Moreover, the observed increase in atrial fibrillation-related hospital activity shows no sign of abating...
  26. ncbi request reprint Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986-95: a retrospective cohort study
    S Capewell
    Department of Public Health, University of Glasgow, Glasgow, UK
    Lancet 358:1213-7. 2001
    ..Most deaths from coronary heart disease occur out of hospital. Hospital patients face social, age, and sex inequalities. Our aim was to examine inequalities and trends in out-of-hospital cardiac deaths...
  27. ncbi request reprint ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects
    D R Murdoch
    Department of Cardiology, Western Infirmary, Glasgow, UK
    Am Heart J 141:800-7. 2001
    ..When added to ACE inhibitors, angiotensin II type 1 (AT1) antagonists may allow more complete blockade of the RAAS and preserve the beneficial effects of bradykinin accumulation not seen with AT1 receptor blockade alone...
  28. ncbi request reprint Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure
    A P Davie
    Medical Research Council Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, UK
    Circulation 100:268-73. 1999
    ....
  29. ncbi request reprint Venous endothelin receptor function in patients with chronic heart failure
    M P Love
    Department of Cardiology, Western General Hospital, Edinburgh EH4 2XU, Scotland, U K
    Clin Sci (Lond) 98:65-70. 2000
    ..Chronic heart failure may be associated with a selective decrease in venous ET(A) receptor sensitivity, but further studies are required to clarify the functional significance of this observation...
  30. ncbi request reprint More 'malignant' than cancer? Five-year survival following a first admission for heart failure
    S Stewart
    Clinical Research Initiative in Heart Failure, University of Glasgow, G12 8QQ, Glasgow, UK
    Eur J Heart Fail 3:315-22. 2001
    ..The prognostic impact of heart failure relative to that of 'high-profile' disease states such as cancer, within the whole population, is unknown...
  31. ncbi request reprint Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans
    J E McDonald
    CRI in Heart Failure, Department of Medicine and Therapeutics, University of Glasgow, Scotland, UK
    Circulation 104:1805-8. 2001
    ..With this specific pharmacological probe, we have shown that a non-ACE pathway capable of generating Ang II exists in human veins in vivo and is potentially functionally important. This pathway is likely to involve the enzyme chymase...
  32. ncbi request reprint Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor
    A P Davie
    Medical Research Council Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, UK
    Hypertension 34:457-60. 1999
    ..The contrast between these findings and previously reported preclinical findings calls into question the relevance of angiotensin-(1-7) to the hemodynamic effects of ACE inhibitors...
  33. ncbi request reprint Endothelium-derived hyperpolarizing factor : identification and mechanisms of action in human subcutaneous resistance arteries
    P Coats
    Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, Scotland
    Circulation 103:1702-8. 2001
    ..We studied the relative importance of EDHF, nitric oxide (NO), and prostacyclin (PGI(2)) as vasodilators in human subcutaneous arteries. We also examined the mechanisms underlying the vasodilator action of EDHF to elucidate its identity...
  34. ncbi request reprint Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease
    P S Jhund
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    J Am Coll Cardiol 37:1367-73. 2001
    ..This effect is lost after three months of therapy, suggesting that tachyphylaxis to one potentially beneficial action of estradiol develops during chronic treatment...
  35. pmc Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure
    D R Murdoch
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
    Heart 82:352-6. 1999
    ..TNFalpha increases secretion of leptin, a hormone which decreases food intake and increases energy expenditure...
  36. pmc Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994
    S Capewell
    University of Glasgow, Department of Public Health, 2 Lilybank Gardens, Glasgow G12 8RZ, UK
    Heart 81:380-6. 1999
    ..To estimate the fall in coronary heart disease (CHD) mortality in Scotland attributable to medical and surgical treatments, and risk factor changes, between 1975 and 1994...
  37. ncbi request reprint Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans
    S D Galloway
    Department of Sports Studies, University of Stirling, Scotland, UK
    Clin Sci (Lond) 99:223-30. 2000
    ..Therefore it can be concluded that reducing sympathetic activity may not be an appropriate strategy to help reduce perceived dyspnoea...
  38. pmc Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population
    T A McDonagh
    Department of Medical Cardiology, University of Glasgow, Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK
    Heart 86:21-6. 2001
    ....
  39. ncbi request reprint Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans
    M C Petrie
    Medical Research Council, Clinical Research Initiative in Heart Failure, University of Glasgow, UK
    J Hypertens 18:61-4. 2000
    ..The aim of this study was to investigate the effect of adrenomedullin on angiotensin II and adrenocorticotrophic hormone-stimulated aldosterone production in vivo in healthy humans...
  40. ncbi request reprint Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries
    P Coats
    School of Biological and Biomedical Sciences, Glasgow Caledonian University, Cowcaddens Road, Scotland, Glasgow, UK
    Cardiovasc Res 49:828-37. 2001
    ..In this study we have examined for the first time the signal transduction mechanisms involved in the generation of pressure-dependent myogenic tone in human small resistance arteries from the subcutaneous vascular bed...
  41. ncbi request reprint Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction
    K MacIntyre
    Department of Public Health, University of Glasgow, Glasgow, Scotland, United Kingdom
    J Am Coll Cardiol 38:729-35. 2001
    ..Overall, men have a higher 30-day case fatality than women. Women do not fare worse than men after AMI when age and other factors are taken into account. However, men are more likely to die before hospitalization...
  42. ncbi request reprint Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure
    M C Petrie
    Department of Cardiology, Western Infirmary, Glasgow, United Kingdom
    Hypertension 38:412-6. 2001
    ....
  43. pmc Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans
    M C Petrie
    Department of Cardiology, Western Infirmary of Glasgow, Glasgow
    Br J Clin Pharmacol 52:165-8. 2001
    ..This provides further evidence of a synergistic interaction between adrenomedullin and atrial natriuretic peptide and suggests that adrenomedullin may have a role in fluid and electrolyte balance and blood pressure regulation...
  44. ncbi request reprint Impaired endothelial function in isolated human uremic resistance arteries
    S T Morris
    The Renal Unit, Western Infirmary, Glasgow, Scotland, United Kingdom
    Kidney Int 60:1077-82. 2001
    ..This present study therefore examined subcutaneous resistance artery function in vitro, comparing adult uremic patients and controls using wire myography...
  45. ncbi request reprint Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure
    P S Jhund
    Clinical Research Initiative in Heart Failure, University of Glasgow, United Kingdom
    J Am Coll Cardiol 37:1234-8. 2001
    ..CONCLUSIONS: In patients with CHF, venodilation occurs within minutes of the administration of intravenous dose of furosemide. Our observation that aspirin inhibits this effect further questions the use of aspirin in patients with CHF...
  46. ncbi request reprint Endothelin receptor antagonism in patients with chronic heart failure
    M P Love
    Department of Cardiology, Southern General Hospital, 1345 Govan Road, G51 4TF, Scotland, Glasgow, UK
    Cardiovasc Res 47:166-72. 2000
    ..Our secondary aim was to examine more closely the effect of chronic heart failure on endothelin biosynthesis...
  47. ncbi request reprint Altered diaphragm position and function in patients with chronic heart failure
    L Caruana
    Department of Cardiology, Western Infirmary, Glasgow G11 6NT, UK
    Eur J Heart Fail 3:183-7. 2001
    ..5+/-8.2 vs. 15.9+/-6.1 mm s(-1), P<0.001). CONCLUSIONS: These data demonstrate that the position and function of the diaphragm is altered in CHF...
  48. ncbi request reprint Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries
    C Berry
    Department of Medicine and Therapeutics, University of Glasgow, Glasgow, UK
    Circulation 101:2206-12. 2000
    ..O(2)(-) production by activation of vascular NAD(P)H oxidase. We studied the sources of.O(2)(-) production in human blood vessels and investigated whether, and by what mechanism, Ang II might alter vascular.O(2)(-) production...
  49. pmc Serious adverse events experienced by patients with chronic heart failure taking spironolactone
    C Berry
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
    Heart 85:E8. 2001
    ..As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops...
  50. pmc Randomised controlled trial of specialist nurse intervention in heart failure
    L Blue
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G12 6NT
    BMJ 323:715-8. 2001
    ..001) and spent fewer days in hospital for heart failure (mean 3.43 v 7.46 days, P=0.0051). CONCLUSIONS: Specially trained nurses can improve the outcome of patients admitted to hospital with heart failure...
  51. ncbi request reprint Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
    Eileen O'Meara
    Department of Cardiology, Western Infirmary, Glasgow, Scotland G11 6NT, United Kingdom
    Eur J Heart Fail 7:650-6. 2005
    ..To evaluate the effect of the angiotensin receptor blocker candesartan on patients' perception of symptoms, using the McMaster Overall treatment evaluation (OTE), in a broad spectrum of patients with chronic heart failure (CHF)...
  52. ncbi request reprint The treatment of heart failure with preserved ejection fraction ("diastolic heart failure")
    Karen Hogg
    Department of Cardiology, Clinical Research Initiative in Heart Failure, University of Glasgow Western Infirmary, Glasgow, G11 6NT, United Kingdom
    Heart Fail Rev 11:141-6. 2006
    ..Large trials are presently underway which are examining the effect of treatment with an ACE inhibitor, ARB and aldosterone antagonist in patients with heart failure and preserved ejection fraction...
  53. ncbi request reprint Economics of chronic heart failure
    C Berry
    MRC, Clinical Research Initiative in Heart Failure, West Medical Building, University of Glasgow, G12 8QQ, Glasgow, UK
    Eur J Heart Fail 3:283-91. 2001
    ..Optimization of drug therapy represents the most effective way of reducing costs. Recent economic analyses in the Netherlands and Sweden suggest the costs of care are rising...
  54. ncbi request reprint Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker
    Colin Berry
    Department of Cardiology, Western Infirmary, and Department of Applied Physiology, University of Strathclyde, Glasgow, UK
    Eur J Heart Fail 9:429-34. 2007
    ..Spironolactone improves prognosis in severe heart failure (HF). We investigated its effects in patients with mild-moderate HF treated with an ACE inhibitor and beta-blocker...
  55. ncbi request reprint Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    Eileen O'Meara
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, UK
    Eur Heart J 25:1920-6. 2004
    ..To evaluate the effect of the angiotensin receptor blocker candesartan on New York Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart failure (CHF)...
  56. ncbi request reprint Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice
    C Berry
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
    Int J Cardiol 81:29-35. 2001
    ..The aim of this study was to investigate the current management and outcomes of electrical cardioversion in unselected patients in ordinary clinical practice...
  57. ncbi request reprint Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure
    Alison Seed
    Department of Cardiology, Western Infirmary, Glasgow, United Kingdom
    Eur J Heart Fail 9:1120-7. 2007
    ..RAAS inhibition can be achieved in a number of ways though an orally active renin inhibitor (RI) has never been studied before. We describe the neurohumoral effects of an RI...
  58. ncbi request reprint CHF: a GP guide to management
    Colin Berry
    Department of Medicine and Therapeutics, Western Infirmary, University of Glasgow
    Practitioner 246:669-72, 675-81. 2002
  59. ncbi request reprint Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis
    Karen Hogg
    Department of Cardiology, Western Infirmary, Glasgow G12 8QQ, Scotland, United Kingdom
    J Am Coll Cardiol 43:317-27. 2004
    ..Though much has recently been learned about the syndrome of HF-PSF, many questions remain to be answered, not least how it should be treated...
  60. ncbi request reprint New therapeutic options in congestive heart failure: Part I
    John McMurray
    Clinical Research Initiative in Heart Failure, University of Glasgow, Scotland
    Circulation 105:2099-106. 2002
  61. pmc Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study
    S Stewart
    Clinical Research Initiative in Heart Failure, Wolfson Building (Level 3, University of Glasgow, Glasgow G12 8QQ, UK
    Heart 86:516-21. 2001
    ..These findings have important implications for the prevention of AF...
  62. ncbi request reprint Neurohumoral pathways in heart failure with preserved systolic function
    Karen Hogg
    Department of Cardiology, Western Infirmary, Glasgow, Scotland
    Prog Cardiovasc Dis 47:357-66. 2005
    ..The role of neurohumoral antagonists in the treatment of heart failure and preserved systolic function has yet to be fully investigated...
  63. ncbi request reprint Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction
    Jens J Thune
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Hypertension 51:48-54. 2008
    ..Whether aggressive antihypertensive treatment can reduce this risk remains unknown...
  64. ncbi request reprint Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme
    Nathaniel M Hawkins
    Stobhill Hospital, Glasgow, UK
    Eur J Heart Fail 9:510-7. 2007
    ..The prognostic implications in HF with preserved systolic function (HF-PSF) are less well understood...
  65. ncbi request reprint Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
    Eldrin F Lewis
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur J Heart Fail 9:83-91. 2007
    ..Limited comparative studies assessing the health-related quality of life (HRQL) in heart failure (HF) patients with preserved vs. low ejection fraction (LVEF) have been disparate...
  66. ncbi request reprint ACE inhibitors in cardiovascular disease--unbeatable?
    John J V McMurray
    N Engl J Med 358:1615-6. 2008
  67. doi request reprint Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    Michael R MacDonald
    Glasgow Royal Infirmary, Glasgow, UK
    Eur Heart J 29:1377-85. 2008
    ..To determine whether the risk of adverse cardiovascular (CV) outcomes associated with diabetes differs in patients with low and preserved ejection fraction (EF) heart failure (HF)...
  68. doi request reprint Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both
    L Michael Prisant
    Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Am Coll Cardiol 51:1865-71. 2008
    ....
  69. doi request reprint Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur Heart J 29:1739-52. 2008
    ..To assess awareness of heart failure (HF) management recommendations in Europe among cardiologists (C), internists and geriatricians (I/G), and primary care physicians (PCPs)...
  70. ncbi request reprint Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 152:500-8. 2006
    ..By examining this international trial population of high-risk patients, we sought to determine geographic variations in the use of 3 key treatments for MI...
  71. doi request reprint High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    Rachel E Anderson
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02445, USA
    Am Heart J 155:706-11. 2008
    ..We examined characteristics, cardiovascular outcomes, and the influence of risk factors on outcomes in young survivors of AMI...
  72. ncbi request reprint Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience
    Kent Stephenson
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Heart Rhythm 4:308-13. 2007
    ....
  73. ncbi request reprint Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, United Kingdom
    N Engl J Med 357:28-38. 2007
    ..A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes...
  74. ncbi request reprint Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Tim Clayton
    Western Infirmary, Glasgow, Scotland, UK
    Circulation 115:3111-20. 2007
    ....
  75. doi request reprint Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study)
    Nagesh S Anavekar
    Department of Cardiology, Austin Health, University of Melbourne, Melbourne, Australia
    Am J Cardiol 101:607-12. 2008
    ..53 (95% CI 1.24 to 1.88) increased risk of fatal and nonfatal CV outcomes. In conclusion, decreased right ventricular systolic function is a major risk factor for death, sudden death, HF, and stroke after MI...
  76. ncbi request reprint Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Satish Kenchaiah
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 116:627-36. 2007
    ..However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality...
  77. ncbi request reprint Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1482-7. 2007
    ....
  78. doi request reprint Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa
    R A P Weir
    Department of Cardiology, Western Infirmary, Glasgow, G11 6NT, United Kingdom Faculty of Medicine, University of Glasgow, United Kingdom
    Eur J Heart Fail 10:157-63. 2008
    ..The CHARM-Added trial describes the largest experience of using multiple inhibitors of the renin-angiotensin-aldosterone system (RAAS) together...
  79. doi request reprint Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus
    Nagesh S Anavekar
    Clinical Trials Unit, Austin Health, University of Melbourne, Melbourne, Australia
    Am J Cardiol 101:925-9. 2008
    ....
  80. ncbi request reprint Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality
    Kevin L Thomas
    Duke Clinical Research Institute, Duke University Medical Center, Durham NC 27710, USA
    Am Heart J 155:87-93. 2008
    ....
  81. ncbi request reprint Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 50:40-7. 2007
    ..The goal of this study was to identify potentially novel laboratory markers of risk in chronic heart failure patients...
  82. ncbi request reprint Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Anique Ducharme
    Montreal Heart Institute, Montreal, Quebec, Canada
    Am Heart J 152:86-92. 2006
    ..CHARM provided the opportunity to prospectively determine the effect of candesartan on the incidence of new AF in this CHF population...
  83. ncbi request reprint Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease
    T Christian H Mix
    Department of Development and Medical Affairs, Amgen Inc, Thousand Oaks, Calif, USA
    Am Heart J 149:408-13. 2005
    ....
  84. ncbi request reprint Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom
    Simon Stewart
    Division of Health Sciences, University of South Australia, City East Campus, Adelaide 5000, Australia
    Int J Cardiol 100:143-9. 2005
    ..The aim of this study was to determine the effects of carvedilol on the costs related to the treatment of severe chronic heart failure (CHF)...
  85. ncbi request reprint Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  86. ncbi request reprint Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials
    James B Young
    Division of Medicine, The Cleveland Clinic Foundation and Kaufman Center for Heart Failure, 9500 Euclid Avenue T 13, Cleveland, OH 44195, USA
    Circulation 110:2618-26. 2004
    ..CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program...
  87. ncbi request reprint Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
    Circulation 110:2180-3. 2004
    ..We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program...
  88. ncbi request reprint Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 351:1285-95. 2004
    ..Renal failure is associated with one of the highest risks, but the influence of milder degrees of renal impairment is less well defined...
  89. ncbi request reprint Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
    David Aguilar
    Cardiovascular Division, University of Texas Health Science Center, 6431 Fannin, MSB 1 246, Houston, TX 77030, USA
    Circulation 110:1572-8. 2004
    ..A prior diagnosis of diabetes mellitus is associated with adverse outcomes after acute myocardial infarction (MI), but the risk associated with a new diagnosis of diabetes in this setting has not been well defined...
  90. ncbi request reprint Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    Karl Swedberg
    Eur Heart J 25:357-8. 2004
  91. ncbi request reprint Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  92. ncbi request reprint Angiotensin receptor blockers in heart failure
    Jan Stergren
    Karolinska Hospital, Stockholm, Sweden
    J Renin Angiotensin Aldosterone Syst 4:171-5. 2003
    ..CHARM-Preserved showed that candesartan can reduce hospital admission for heart failure in patients with preserved systolic function though more definitive outcome data are needed in this group...
  93. ncbi request reprint Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  94. ncbi request reprint Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 352:2581-8. 2005
    ..We assessed the risk and time course of sudden death in high-risk patients after myocardial infarction...
  95. ncbi request reprint Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    Am Heart J 150:46-53. 2005
    ..Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated...
  96. ncbi request reprint Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    Shelby D Reed
    Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am Heart J 150:323-9. 2005
    ..We conducted a prospective economic evaluation to compare within-trial resource use, costs, and quality of life in patients receiving valsartan, captopril, or both after MI...
  97. ncbi request reprint Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Rajesh Janardhanan
    Division of Cardiology, Brigham and Women s Hospital, Boston, MA02115, USA
    Am Heart J 152:183-9. 2006
    ..It is not known, however, whether the extent of coronary artery disease (CAD) independently influences cardiovascular (CV) outcomes in these high-risk patients...
  98. ncbi request reprint Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
    Lars G Olsson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Am Coll Cardiol 47:1997-2004. 2006
    ....
  99. ncbi request reprint Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program
    Anique Ducharme
    Montreal Heart Institute, Montreal, Canada
    Am Heart J 151:985-91. 2006
    ..CHARM provided the opportunity to prospectively determine the effect of candesartan on the incidence of new AF in this CHF population...
  100. ncbi request reprint Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  101. ncbi request reprint Renal function as a predictor of outcome in a broad spectrum of patients with heart failure
    Hans L Hillege
    Medical Center Groningen, University of Groningen, The Netherlands
    Circulation 113:671-8. 2006
    ..The aim of this analysis was to evaluate the prognostic importance of renal function in a broader spectrum of patients with CHF...